Results 221 to 230 of about 402,660 (356)

The dopaminergic system in neurodevelopment: preclinical models of neurodevelopmental disorders and susceptibility to neurodegeneration. [PDF]

Front Cell Neurosci
Santoni M, Mastio A, Pistis M, Sagheddu C.   +3 more
europepmc   +1 more source

Surprise Marketing

Psychology &Marketing, EarlyView.
ABSTRACT Surprise marketing, characterized by unexpected tactics such as blind boxes and spontaneous discounts, captivates consumers by sparking curiosity and participation. Despite increasing industry use, scholarly research remains fragmented and limited.
Xin‐Jean Lim, Weng Marc Lim, Park Thaichon   +2 more
wiley   +1 more source

Resting-State Activity and Connectivity of Dopaminergic Key Areas and Outcome After a Severe Stroke. [PDF]

Eur J Neurosci
Braaß H, Asmussen L, Backhaus W, Higgen FL, Koch PJ, Wrobel P, Choe CU, Quandt F, Frey B, Schulz R.   +9 more
europepmc   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice

Proceedings of the National Academy of Sciences of the United States of America, 2016
Pavle Matak, Andrija Matak, S. Moustafa, Dipendra K. Aryal, E. Benner, W. Wetsel, N. Andrews   +6 more
semanticscholar   +1 more source

A High-Throughput, High-Content Analysis of Dopaminergic Neurodegeneration in <i>Caenorhabditis elegans</i> Exposed to Per- and Polyfluoroalkyl Substances. [PDF]

Toxics
Benson D, Currie S, Wang JS, Tang L.
europepmc   +1 more source

Brain Imaging Changes Following Deep Brain Stimulation Patients with Parkinson's Disease: A Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's Disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Structural brain changes, including atrophy in the midbrain, basal ganglia, and cortical regions such as the frontal and temporal lobes, are observed in advanced stages.
Suraiya Mangra, Stanislaw Szlufik, Chao‐Kai Hu, Alexandre Boutet, Jürgen Germann, Andres M. Lozano   +5 more
wiley   +1 more source

Modulation of Oxidative Stress and Apoptosis by Antrodia cinnamomea-Loaded Citrate-Stabilized Silver Nanoparticles in Experimental Parkinsonism. [PDF]

Mol Neurobiol
Tekiner D, Gedikli S, Gelen V, Bayram C, Kara A.   +4 more
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Parkinson's disease: pathogenesis and therapeutic strategies. [PDF]

Mol Biomed
Zhang S, Wang T, Peng Y, Wang Q, Zhang Z, Chu S, Huang H, Chen N.   +7 more
europepmc   +1 more source